Peter DeYoung
#304CEO (Global Pharma & Executive Director)
48
Age
25y
Exp
14y
Tenure
6/10
Risk
🎓 BSE (Engineering) · Princeton University
📜 MBA · Stanford Graduate School of Business
🏛️ Global-Elite
CompensationTBP
Personality
6
Open
7
Cons
5
Extr
6
Agre
3
Neur
Piramal Pharma
Healthcare · Mid Cap
Distressed / Turnaround · Performance-Driven
About
Peter DeYoung is the CEO (Global Pharma & Executive Director) of Piramal Pharma, a Mid Cap company in the Healthcare sector with a market cap of ₹20K Cr. A Transformational leader with 25 years of experience, he is known for data-driven decision-making and aggressive acquirer strategy. Emphasizes the integration of corporate culture and governance standards while navigating complex demerger processes.
FAQ
What is Peter DeYoung's leadership style?
Peter DeYoung is classified as a Transformational leader. He is data-driven in decision-making, with a dynasty builder motivation and steady-marathon pace of execution.
What is Peter DeYoung's educational background?
Peter DeYoung holds a BSE (Engineering) from Princeton University and a MBA from Stanford Graduate School of Business.
Who is the CEO of Piramal Pharma?
Peter DeYoung is the CEO (Global Pharma & Executive Director) of Piramal Pharma. He has been with the company for 14 years and in the current role for 7 years.
Leadership DNA
ArchetypeTransformational
MotivationDynasty Builder
CrisisRestructurer
DecisionData-Driven
GrowthAggressive Acquirer
PeopleNumbers Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerDemanding Machine
BrandTechnical-Expert
FocusTalent & Culture
OrientationDeep Specialist
Leadership Evidence
“Emphasizes the integration of corporate culture and governance standards while navigating complex demerger processes.”
⚡ Crisis●●●●○
He spearheaded the complex demerger of Piramal Pharma from the parent conglomerate to create a focused, pure-play pharmaceutical entity.
🎯 Motivation●●●●○
As a member of the Piramal family, his leadership is central to the long-term stewardship and strategic evolution of the family-controlled pharmaceutical business.
👥 People●●●●○
His leadership style is explicitly characterized by a data-driven approach to operational efficiency and performance management within the global pharma business.
📈 Growth●●●●●
He has been instrumental in the integration of major acquisitions like the $2.3 billion purchase of the Cold Chain business and other strategic global manufacturing assets.
💡 Innovation●●●●○
The company focuses on complex generics and CDMO services, prioritizing the efficient scaling of proven drug molecules and delivery platforms.
🏃 Pace●●●●○
The business operates on long-term CDMO contracts and a methodical pipeline of generic drug approvals, requiring consistent regulatory compliance and operational stability.
🌱 Purpose●●●○○
As part of the Piramal Group, the company integrates ESG frameworks and sustainability reporting into its operational strategy alongside commercial growth.
🏷️ Brand●●●●○
The company's market reputation is built on its specialized manufacturing capabilities, complex chemistry expertise, and global regulatory certifications.
🤝 Customer●●●●●
Piramal Pharma is primarily a B2B player, providing contract development and manufacturing services to global pharmaceutical and biotech companies.
💼 Employer●●●○○
The company's turnaround phase and focus on performance-driven metrics necessitate high-pressure execution and aggressive target achievement.
📋 Mandate
The business needs to optimize its complex debt profile and streamline operational profitability following its recent structural demerger and integration phase.
🏢 Culture
Undergoing significant turnaround efforts requiring intense focus on operational KPIs and aggressive growth milestones.
Financials
Revenue FY25₹9K Cr
PAT FY25₹91 Cr
Rev CAGR 5Y11.9%
OPM7.5%
NPM1%
ROE1.1%
ROCE5.7%
P/E—
Fwd P/E56.9
P/B—
D/E60.1
Promoter54.6%
Institutional20.4%
Mkt Cap₹20K Cr
Compensation
To Be Published
Data being verified from audited reports
